Mebeverin Aristo (Mebeverine Hydrochloride)

Mebeverine Hydrochloride acts on gastrointestinal smooth muscle to relieve spasm and associated discomfort.

• Irritable bowel syndrome (IBS): reduces abdominal pain, bloating and irregular bowel movements.
• Functional bowel disorders: eases cramping and improves bowel habit regularity.
• Abdominal pain and cramps: provides symptomatic relief by relaxing intestinal smooth muscle.
• Spastic colon: diminishes colonic spasms and associated discomfort.
• Travel‑related diarrhea with cramping: helps control intestinal hypermotility.

• Mebeverine Hydrochloride exerts its antispasmodic effect by directly relaxing gastrointestinal smooth muscle. The compound interferes with calcium influx into smooth‑muscle cells and modulates muscarinic receptor activity, leading to reduced intracellular calcium concentration. This action diminishes muscle contractility without significant anticholinergic activity, allowing normalization of gut motility and relief of spasm‑related pain. The effect is localized to the gastrointestinal tract, minimizing systemic side effects.

Mebeverine Hydrochloride may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild stomach upset that usually resolves without intervention.
• Dry mouth: reduced salivation causing a transient feeling of thirst.
• Headache: mild to moderate head pain occurring shortly after dosing.
• Dizziness: transient light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or difficulty breathing requiring immediate medical attention.
• Severe skin eruption: Stevens‑Johnson syndrome or toxic epidermal necrolysis, though extremely rare.
• Angioedema: rapid swelling of face, lips or tongue, potentially life‑threatening.
• Cardiac arrhythmia: irregular heartbeat reported in isolated cases.

Before initiating therapy with Mebeverine Hydrochloride, several precautionary measures should be considered.

• Assess renal and hepatic function: adjust use if significant impairment is present.
• Use cautiously in the elderly: increased sensitivity to antispasmodic effects may occur.
• Avoid in patients with known hypersensitivity to mebeverine or excipients.
• Monitor for cardiac symptoms: report palpitations or irregular heartbeat promptly.
• Review concomitant medications: potential additive anticholinergic effects should be evaluated.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mebeverine Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with other potent antispasmodics: may cause excessive smooth‑muscle relaxation and constipation.
• Co‑administration with strong anticholinergic agents: increases risk of dry mouth, blurred vision and urinary retention.
• Concurrent use with CYP3A4 inhibitors (e.g., ketoconazole): may raise mebeverine plasma levels, heightening adverse effects.

Moderate Interactions (Monitor Closely)

• Antihistamines (e.g., diphenhydramine): monitor for additive anticholinergic symptoms.
• Tricyclic antidepressants: observe for enhanced gastrointestinal motility changes.
• Digoxin: watch for potential alterations in drug absorption due to changes in gut motility.